Sorrento's R&D imayang'ana kwambiri pakuyendetsa luso mu COVID-19, chithandizo cha khansa, kuwongolera ululu komanso matenda a autoimmune.

Mapulogalamu Ofunika	Chizindikiro	Zowonongeka	Phase I	Phase II	Gawo III/Pivotal	Fomu ya FDA
Mapulogalamu a COVID-19
COVISTIX™ (zachidziwitso) Rapid Antigen Test 0%* Kugwiritsa Ntchito Mwadzidzidzi Authorization (EUA) ku Mexico (COFEPRIS), Brazil (ANVISA), ndi CE Yolembedwa ku Europe COVIMARK™ (zachidziwitso) Rapid Antigen Test 0%* Kufunsira kwatumizidwa ku US ndi Canada kwa Authorization Emergency Use (EUA) Chithunzi cha VIREX (zachidziwitso) Kunyumba Diagnostic 60.2%* EUA Enabling Studies in Q3 2022 OQORY™ (COVI-MSC) ARDS chifukwa cha COVID-19 ku ICU Odwala 82%* Kuyesa Kwambiri ku Brazil                           OVYDSO (Olgotrelvir) Anti-viral (Piritsi Mkamwa) 40%* Katemera wa Omicron mRNA katemera 20%*
Mapulogalamu Ofunika	Chizindikiro	Zowonongeka	Phase I	Phase II	Gawo III/Pivotal	Fomu ya FDA
immunotherapy
FUJOVEE™ (Abivertinib) Zamgululi 82%* FUJOVEE™ (Abivertinib) B Ma cell Lymphomas 60.2%* FUJOVEE™ (Abivertinib) Prostate 20%* PD-L1 (Socazolimab)* Mtengo wa SCLC 82%* *Mumgwirizano ndi Lee's Pharm ku China PD-L1 (STI-3031)** Cancer khomo lachiberekero 82%* **Ku US komanso mogwirizana ndi ImmuneOncia ku Korea CD47 Zotupa Zolimba 40%* CD38 DAR-T angapo Myeloma 40%* CD38 ADC Amyloidosis, Multiple Myeloma, T-ALL, ndi esophageal 40%* TROP2 ADC* Zotupa Zolimba 40%* Seprehvec™ oncolytic virus Zotupa Zolimba; Zotupa za CNS 40%* BCMA ADC Zotupa Zamadzimadzi 20%* Bevacizumab-ADAB™ Khansa ya Endometrial 40%* Mogwirizana ndi Mayo Clinic Bevacizumab-ADAB™ Katemera wa ovarian 40%* Mogwirizana ndi Mayo Clinic Rituximab-ADAB™ B-cell Lymphomas 40%* Mogwirizana ndi Mayo Clinic Sofusa® anti-PD-1 Matenda a T-Cell Lymphoma (CTCL), Melanoma 40%*
Mapulogalamu Ofunika	Chizindikiro	Zowonongeka	Phase I	Phase II	Gawo III/Pivotal	Fomu ya FDA
ululu
ZTlido® 1.8% Postherpetic Neuralgia - PHN 99.8%* Gloperba® Chithandizo cha Gout (Oral) 99.8%* SEMEXA (SP-102) Lumbar Radicular / Sciatica Pain 82%* SP-103 (Lidocaine Topical System 5.4%) Ululu Wopweteka Kwambiri 60.2%* SP-104 (Kuchedwa Kuphulika Mlingo Wochepa Naltrexone) Fibromyalgia 20%* RTX (resiniferatoxin) Epidural jakisoni Ululu Wosasinthika mu Advanced Cancer 60.3%* Dzina la ana amasiye RTX (resiniferatoxin) Njira ya intra-articular Kupweteka Kwambiri kwa Knee mpaka Bondo 60.2%*
Mapulogalamu Ofunika	Chizindikiro	Zowonongeka	Phase I	Phase II	Gawo III/Pivotal	Fomu ya FDA
Lymphatic Drug Delivery
Sofusa® odana ndi TNF Autoimmune (RA) 40%* Sofusa® anti-PD-1 Matenda a T-Cell Lymphoma (CTCL), Melanoma 40%* Sofusa® anti-CTLA-4 Melanoma 40%* Mogwirizana ndi Mayo Clinic

Mapulogalamu a COVID-19
Mapulogalamu Ofunika (Chizindikiro)	Phase
COVISTIX™ (zachidziwitso) FDA EUA COVIMARK™ (zachidziwitso) FDA EUA Chithunzi cha VIREX (zachidziwitso) PH III FUJOVEE™ (Abivertinib) Ph III OQORY™ (COVI-MSC) Ph III OVYDSO (Olgotrelvir) Ph II Katemera wa Omicron mRNA Zowonongeka

immunotherapy
Mapulogalamu Ofunika (Chizindikiro)	Phase
FUJOVEE™ (Abivertinib) Ph III FUJOVEE™ (Abivertinib) Ph II FUJOVEE™ (Abivertinib) Zowonongeka PD-L1 (Socazolimab)* Ph III PD-L1 (STI-3031)** Ph III CD47 (Zotupa Zolimba) Ph I CD38 DAR-T (Multiple Myeloma) Ph I CD38 ADC (Amyloidosis, Multiple Myeloma, T-ALL, ndi esophageal) Ph I TROP2 ADC* (Zotupa Zolimba) Ph I Seprehvec™ oncolytic virus (Zotupa Zolimba; Zotupa za CNS) PH ndi BCMA ADC (Zotupa zamadzimadzi) Zowonongeka Bevacizumab-ADAB™ (Cancer ya Endometrial) Ph I Bevacizumab-ADAB™ (Cancer ya Ovarian) Ph I Rituximab-ADAB™ (B-cell Lymphomas) Ph I Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I

ululu
Mapulogalamu Ofunika (Chizindikiro)	Phase
ZTlido® 1.8% (Postherpetic Neuralgia - PHN) Fomu ya FDA Gloperba® 1.8% Chithandizo cha Gout (Oral) Fomu ya FDA SEMEXA (SP-102) Ph III SP-103 (Lidocaine Topical System 5.4%) Ph II SP-104 (Kuchedwa Kuphulika Mlingo Wochepa Naltrexone) Zowonongeka RTX (resiniferatoxin) Epidural jakisoni Ph II RTX (resiniferatoxin) Njira ya intra-articular Ph II

Kutumiza kwa Lymphatic
Mapulogalamu Ofunika (Chizindikiro)	Phase II
Sofusa® odana ndi TNF (Autoimmune RA) Ph I Sofusa® anti-PD-1 (Cutaneous T-Cell Lymphoma (CTCL), Melanoma) Ph I Sofusa® anti-CTLA-4 (Khansa ya pakhungu) Ph I